Arcturus Collaboration

As part of a collective effort in fighting COVID-19, ImmunoScape is collaborating with Arcturus Therapeutics, a developer of RNA therapeutics for treatment and prevention of diseases with high unmet medical needs, and Duke-NUS, who will be running the clinical trial in healthy subjects in Singapore. The Arcturus LUNAR-COV19 vaccine, which uses Arcturus proprietary STARR™ and LUNAR® technologies is based on self-replicating mRNA coding for the SARS-CoV-2 spike protein. The vaccine has already demonstrated promising immune responses in animal studies and ImmunoScape will use its signature assay, TargetScape®, to perform high-dimensional immune profiling for longitudinally monitoring the magnitude and quality of spike-specific CD8+ T cells and other T cell subsets induced in vaccinated subjects, and modelling the evolution of the immune response during vaccination.